Bloqueo del Plano Intercostal Serrato Posterior Superior Versus Morfina Intratecal en VATs
Comparación de los Efectos del Bloqueo del Plano Intercostal del Serrato Posterior Superior y la Morfina Intratecal sobre el Dolor Agudo Postoperatorio en Pacientes Sometidos a Cirugía Toracoscópica Videoasistida
This study aims to compare the analgesic effects of the serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.
This is a prospective, randomized, controlled, single-center clinical trial including adult patients undergoing elective thoracoscopic surgery. Participants will be randomly assigned to receive either a serratus posterior superior intercostal plane block or intrathecal morphine before general anesthesia.
The primary outcome is cumulative opioid consumption during the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents. Secondary outcomes include pain scores, time to first analgesic request, quality of recovery, and postoperative complications.
The study aims to determine whether these two techniques differ in their effectiveness for postoperative pain management.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This study is a prospective, randomized, controlled, single-blinded, parallel-group clinical trial designed to compare the analgesic efficacy of serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.
Eligible patients aged 18-75 years with American Society of Anesthesiologists physical status I-III scheduled for elective thoracoscopic procedures (wedge resection, segmentectomy, or lobectomy) will be included. Patients will be randomized in a 1:1 ratio using a computer-generated sequence with block randomization.
Participants in the serratus posterior superior intercostal plane block group will receive an ultrasound-guided regional block prior to the induction of general anesthesia. Participants in the intrathecal morphine group will receive an intrathecal morphine injection before general anesthesia. All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia.
The primary outcome is cumulative opioid consumption within the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents.
Secondary outcomes include opioid consumption at 12 hours, numeric rating scale pain scores at rest and during activity, time to first analgesic request, quality of recovery scores, postoperative nausea and vomiting, sedation levels, pruritus, respiratory depression, and postoperative complications up to 30 days.
This study aims to evaluate the relative effectiveness of these two analgesic techniques and to improve postoperative pain management strategies in thoracic surgery.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Samsun
-
Atakent, Samsun, Turquía (Türkiye), 55270
- Ondokuz Mayis University
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age between 18 and 75 years
- American Society of Anesthesiologists physical status I to III
- Scheduled for elective video-assisted thoracoscopic surgery, including wedge resection, segmentectomy, or lobectomy
Exclusion Criteria:
- Refusal to participate
- Pregnancy
- Morbid obesity (body mass index greater than 40 kg per square meter)
- Allergy to study medications
- Neuropsychiatric disorders, cognitive impairment, or inability to communicate
- History of substance abuse
- Active systemic infection or infection at the planned injection site
- Severe cardiac, respiratory, hepatic, renal, or endocrine disease.
- Chronic pain syndrome or ongoing chronic pain treatment
- Emergency surgery or previous ipsilateral VATS or thoracotomy
- Preoperative opioid use: ≥15 mg oral morphine equivalents/day for ≥30 days within the previous 3 months.
- Anticipated need for postoperative mechanical ventilation.
- Contraindications to neuraxial or peripheral regional anesthesia, including anticoagulant therapy, coagulopathy, infection, or relevant anatomical abnormalities.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Intrathecal Morphine
Participants receive intrathecal morphine before induction of general anesthesia. Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine. |
Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally before induction of general anesthesia. |
|
Experimental: Serratus Posterior Superior Intercostal Plane Block
Participants receive an ultrasound-guided serratus posterior superior intercostal plane block before induction of general anesthesia. A total of 30 milliliters of 0.25 percent bupivacaine with epinephrine is administered into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine. |
Ultrasound-guided serratus posterior superior intercostal plane block is performed before induction of general anesthesia using 30 milliliters of 0.25 percent bupivacaine with epinephrine injected into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cumulative IV-MME during the first 24 hours after postoperative admission following extubation
Periodo de tiempo: 24 hours
|
Total opioid consumption during the first 24 postoperative hours is expressed as intravenous morphine milligram equivalents, including patient-controlled analgesia and rescue analgesia. |
24 hours
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cumulative IV-MME during the first 12 hours after postoperative admission following extubation
Periodo de tiempo: 12 hours
|
Total opioid consumption during the first 12 postoperative hours expressed as intravenous morphine milligram equivalents |
12 hours
|
|
Postoperative pain scores
Periodo de tiempo: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Pain intensity assessed using the 11-point Numeric Rating Scale (NRS; 0-10), where higher scores indicate greater pain intensity, with 0 representing no pain and 10 representing the worst imaginable pain, measured at rest and during activity. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Time to first patient-controlled analgesia demand
Periodo de tiempo: 24 hours
|
Time from postoperative admission to the first PCA morphine demand. |
24 hours
|
|
Quality of recovery score
Periodo de tiempo: Preoperative baseline, 24 hours postoperatively, and at discharge
|
Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15; total score range 0-150), a validated patient-reported outcome measure where higher scores indicate better postoperative recovery. |
Preoperative baseline, 24 hours postoperatively, and at discharge
|
|
Postoperative nausea and vomiting
Periodo de tiempo: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Postoperative nausea and vomiting (PONV) will be assessed using a 4-point ordinal scale (0-3), where 0 indicates no nausea or vomiting, 1 indicates nausea without vomiting, 2 indicates a single episode of vomiting, and 3 indicates multiple episodes of vomiting; higher scores indicate worse symptoms. Scores >1 will be treated with ondansetron 4 mg IV; persistent symptoms will be treated with intravenous metoclopramide. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Sedation level
Periodo de tiempo: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Sedation level assessed using the Ramsay Sedation Scale (RSS; 1-6), a validated ordinal scale where higher scores indicate deeper sedation, with 1 representing anxiety/agitation and 6 representing no response to stimuli. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Respiratory depression
Periodo de tiempo: 24 hours
|
Incidence of respiratory depression defined as oxygen saturation below 90 percent or respiratory rate below 8 breaths per minute |
24 hours
|
|
Pruritus
Periodo de tiempo: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Incidence and severity of postoperative pruritus assessed using a 4-point ordinal scale (0-3), where 0 = no pruritus, 1 = mild pruritus (itching without scratching), 2 = moderate pruritus (itching with scratching), and 3 = severe pruritus requiring treatment; higher scores indicate worse symptoms. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Block-related complications
Periodo de tiempo: Up to 30 days postoperatively
|
Incidence of post-dural puncture headache, paresthesia, hematoma, and local anesthetic systemic toxicity associated with the study interventions. |
Up to 30 days postoperatively
|
|
Postoperative complications
Periodo de tiempo: 30 days
|
Postoperative complications assessed using the Clavien-Dindo classification, where higher grades indicate more severe complications. |
30 days
|
|
Remifentanil consumption
Periodo de tiempo: Intraoperative period (from induction to end of surgery), up to 4 hours
|
Total intraoperative remifentanil consumption administered during surgery, measured in micrograms (µg). |
Intraoperative period (from induction to end of surgery), up to 4 hours
|
|
Rescue analgesia requirement
Periodo de tiempo: 24 hours
|
Incidence of patients requiring additional analgesia beyond patient-controlled analgesia |
24 hours
|
|
Incidence of postoperative nausea and/or vomiting
Periodo de tiempo: 24 hours postoperatively
|
Incidence of postoperative nausea and vomiting (PONV), defined as the occurrence of at least one episode of nausea and/or vomiting within the first 24 hours postoperatively (yes/no). Patients experiencing at least one episode will be classified as having PONV. |
24 hours postoperatively
|
|
Propofol consumption
Periodo de tiempo: Intraoperative period (from induction to end of surgery), up to 4 hours
|
Total intraoperative propofol consumption administered during surgery, measured in milligrams (mg). |
Intraoperative period (from induction to end of surgery), up to 4 hours
|
|
Area under the numeric rating scale-time curve
Periodo de tiempo: 0 to 24 hours postoperatively
|
The area under the numeric rating scale-time curve from 0 to 24 postoperative hours will be calculated separately for pain at rest and during activity using pain scores measured at 0, 3, 6, 12, 18, and 24 hours and the trapezoidal rule. Higher values indicate a greater cumulative pain burden. |
0 to 24 hours postoperatively
|
|
Comprehensive Complication Index
Periodo de tiempo: Up to 30 days postoperatively
|
Overall postoperative morbidity will be quantified using the Comprehensive Complication Index, which integrates all postoperative complications graded according to the Clavien-Dindo classification into a continuous score ranging from 0 to 100. Higher scores indicate greater overall morbidity. |
Up to 30 days postoperatively
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- SPSIPITM1
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .